M. Abzug, M. Warshaw, and H. Rosenblatt, Immunogenicity and Immunologic Memory after Hepatitis B Virus Booster Vaccination in HIV???Infected Children Receiving Highly Active Antiretroviral Therapy, The Journal of Infectious Diseases, vol.200, issue.6, pp.935-981, 2009.
DOI : 10.1086/605448

M. Abzug, S. Pelton, and L. Song, Immunogenicity, Safety, and Predictors of Response After a Pneumococcal Conjugate and Pneumococcal Polysaccharide Vaccine Series in Human Immunodeficiency Virus-Infected Children Receiving Highly Active Antiretroviral Therapy, The Pediatric Infectious Disease Journal, vol.25, issue.10, pp.920-929, 2006.
DOI : 10.1097/01.inf.0000237830.33228.c3

M. Abzug, L. Song, and T. Fenton, Pertussis Booster Vaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy, PEDIATRICS, vol.120, issue.5, pp.1190-1202, 2007.
DOI : 10.1542/peds.2007-0729

I. Attar, J. Reisman, M. Muehlmann, and K. Mcintosh, Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children Retrospective study Belaunzarán-Zamudio PF, García-León ML, Wong-Chew RM, et al.Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART, Pediatr Infect Dis JVaccine, vol.14, issue.27, pp.149-51, 1995.

V. Falcó, Q. Jordano, and M. Cruz, Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: One year follow-up study, Vaccine, vol.24, issue.14, pp.2567-74, 2006.
DOI : 10.1016/j.vaccine.2005.12.021

C. Farquhar, D. Wamalwa, and S. Selig, Immune Responses to Measles and Tetanus Vaccines Among Kenyan Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Children Pre- and Post-Highly Active Antiretroviral Therapy and Revaccination, The Pediatric Infectious Disease Journal, vol.28, issue.4, pp.295-304, 2009.
DOI : 10.1097/INF.0b013e3181903ed3

S. Fernandes, N. Slhessarenko, and F. Souto, Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine, Vaccine, vol.26, issue.8, pp.1032-1039, 2008.
DOI : 10.1016/j.vaccine.2007.12.020

D. Gibb, A. Giacomelli, and J. Masters, Persistence of Antibody Responses to Haemophilus influenzae Type b Polysaccharide Conjugate Vaccine in Children with Vertically Acquired Human Immunodeficiency Virus Infection, The Pediatric Infectious Disease Journal, vol.15, issue.12, pp.1097-101, 1996.
DOI : 10.1097/00006454-199612000-00008

J. Glaser, S. Volpe, A. Aguirre, H. Simpkins, and G. Schiffman, Zidovudine Improves Response to Pneumococcal Vaccine among Persons with AIDS and AIDS-Related Complex, Journal of Infectious Diseases, vol.164, issue.4, pp.761-765, 1991.
DOI : 10.1093/infdis/164.4.761

C. Hung, S. Chang, and C. Su, A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy*, HIV Medicine, vol.205, issue.1, pp.54-63, 2010.
DOI : 10.1111/j.1468-1293.2009.00744.x

C. Kemper, A. Zolopa, J. Hamilton, M. Fenstersheib, G. Bhatia et al., Prevalence of measles antibodies in adults with HIV infection, AIDS, vol.6, issue.11, pp.1321-1326, 1992.
DOI : 10.1097/00002030-199211000-00013

J. King, . Jr, P. Vink, and I. Chang, Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age, Vaccine, vol.16, issue.4, pp.361-366, 1998.
DOI : 10.1016/S0264-410X(97)80914-0

F. Kroon, V. Dissel, J. Ravensbergen, E. Nibbering, P. Van-furth et al., Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults, Vaccine, vol.19, issue.7-8, pp.886-94, 2000.
DOI : 10.1016/S0264-410X(00)00232-2

M. Levin, A. Gershon, A. Weinberg, L. Song, T. Fentin et al., T Cells, The Journal of Infectious Diseases, vol.194, issue.2, pp.247-55, 2006.
DOI : 10.1086/505149

C. Lu, C. Hung, and Y. Chuang, Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients, Vaccine, vol.30, issue.24, pp.3526-3559, 2012.
DOI : 10.1016/j.vaccine.2012.03.070

S. Madhi, P. Adrian, and L. Kuwanda, Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine, Vaccine, vol.25, issue.13, pp.2451-2458, 2007.
DOI : 10.1016/j.vaccine.2006.09.019

S. Madhi, K. Klugman, L. Kuwanda, C. Cutland, H. Käyhty et al., Quantitative and Qualitative Anamnestic Immune Responses to Pneumococcal Conjugate Vaccine in HIV???Infected and HIV???Uninfected Children 5 Years after Vaccination, The Journal of Infectious Diseases, vol.199, issue.8, pp.1168-76, 2009.
DOI : 10.1086/597388

F. Mascart-lemone, M. Gérard, and M. Libin, Differential Effect of Human Immunodeficiency Virus Infection on the IgA and IgG Antibody Responses to Pneumococcal Vaccine, Journal of Infectious Diseases, vol.172, issue.5, pp.1253-60, 1995.
DOI : 10.1093/infdis/172.5.1253

H. Nielsen, B. Kvinesdal, T. Benfield, J. Lundgren, and H. Konradsen, Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection, Scand J Infect Dis, vol.30, pp.597-601, 1998.

J. Pacanowski, K. Lacombe, and P. Campa, Plasma HIV-RNA Is the Key Determinant of Long-Term Antibody Persistence After Yellow Fever Immunization in a Cohort of 364 HIV-Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.59, issue.4, pp.360-367, 2012.
DOI : 10.1097/QAI.0b013e318249de59

S. Pensieroso, A. Cagigi, and P. Palma, Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children, Proceedings of the National Academy of Sciences, vol.106, issue.19, pp.7939-7983, 2009.
DOI : 10.1073/pnas.0901702106

S. Pessoa, M. Miyamoto, E. Ono, A. Gouvêa, D. Moraes-pinto et al., Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART, Vaccine, vol.28, issue.6, pp.1606-1618, 2010.
DOI : 10.1016/j.vaccine.2009.11.045

V. Peters and S. Sood, IMMUNITY TO HAEMOPHILUS INFLUENZAE TYPE b AFTER REIMMUNIZATION WITH OLIGOSACCHARIDE CRM197 CONJUGATE VACCINE IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION, The Pediatric Infectious Disease Journal, vol.16, issue.7, pp.711-714, 1997.
DOI : 10.1097/00006454-199707000-00015

J. Powis, J. Raboud, M. Ostrowski, M. Loutfy, C. Kovacs et al., The Recombinant Hepatitis B Surface Antigen Vaccine in Persons With HIV: Is Seroconversion Sufficient for Long-term Protection?, Journal of Infectious Diseases, vol.205, issue.10, pp.1534-1542, 2012.
DOI : 10.1093/infdis/jis243

T. Puthanakit, L. Aurpibul, S. Yoksan, T. Sirisanthana, and V. Sirisanthana, A 3-year follow-up of antibody response in HIV-infected children with immune recovery vaccinated with inactivated Japanese encephalitis vaccine, Vaccine, vol.28, issue.36, pp.5900-5902, 2010.
DOI : 10.1016/j.vaccine.2010.06.048

M. Rodriguez-barradas, J. Groover, and C. Lacke, IgG Antibody to Pneumococcal Capsular Polysaccharide in Human Immunodeficiency Virus-Infected Subjects: Persistence of Antibody in Responders, Revaccination in Nonresponders, and Relationship of Immunoglobulin Allotype to Response, Journal of Infectious Diseases, vol.173, issue.6, pp.1347-53, 1996.
DOI : 10.1093/infdis/173.6.1347

G. Siberry, R. Coller, and E. Henkle, ANTIBODY RESPONSE TO HEPATITIS A IMMUNIZATION AMONG HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN AND ADOLESCENTS, The Pediatric Infectious Disease Journal, vol.27, issue.5, pp.465-473, 2008.
DOI : 10.1097/INF.0b013e31816454a3

S. Siriaksorn, T. Puthanakit, T. Sirisanthana, and V. Sirisanthana, Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy, Vaccine, vol.24, issue.16, pp.3095-3104, 2006.
DOI : 10.1016/j.vaccine.2006.01.045

V. Spoulou, D. Tsoumas, V. Papaevangelou, G. Mostrou, and M. Theodoridou, Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children, Vaccine, vol.23, issue.46-47, pp.5289-93, 2005.
DOI : 10.1016/j.vaccine.2005.06.002

E. Talesnik, P. Vial, J. Labarca, C. Méndez, and X. Soza, Time Course of Antibody Response to Tetanus Toxoid and Pneumococcal Capsular Polysaccharides in Patients Infected With HIV, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol.19, issue.5, pp.471-478, 1998.
DOI : 10.1097/00042560-199812150-00005

P. Tattevin, A. Depatureaux, and J. Chapplain, Yellow fever vaccine is safe and effective in HIV-infected patients, AIDS, vol.18, issue.5, pp.825-832, 2004.
DOI : 10.1097/00002030-200403260-00020

M. Tejiokem, I. Gouandjika, and L. Béniguel, HIV-Infected Children Living in Central Africa Have Low Persistence of Antibodies to Vaccines Used in the Expanded Program on Immunization, PLoS ONE, vol.20, issue.12, p.1260, 2007.
DOI : 10.1371/journal.pone.0001260.t004
URL : https://hal.archives-ouvertes.fr/pasteur-00285753

O. Veit, M. Niedrig, and C. Chapuis-taillard, Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV???Infected Patients, Clinical Infectious Diseases, vol.48, issue.5, pp.659-66, 2009.
DOI : 10.1086/597006

C. Zaccarelli-filho, E. Ono, and D. Machado, HIV-1-infected children on HAART: Immunologic features of three different levels of viral suppression, Cytometry Part B: Clinical Cytometry, vol.42, issue.1, pp.14-21, 2007.
DOI : 10.1002/cyto.b.20152